Thursday, February 7, 2013
Biogen Idec will take over full ownership of the multiple sclerosis treatment Tysabri from its partner Irish drugmaker Elan Corp.
Biogen Idec will take over full ownership of the multiple sclerosis treatment Tysabri from its partner Irish drugmaker Elan Corp.